Lower GI 2017

Adaptive RT: background I

- Proven dose-effect response in RT+CHT regimens… boosting the tumor/mesorectum may increase pCR and major response rates

- Toxicity limits: exploring feasible protocols

- Exploiting acceleration (importance of repopulation) …reducing treatment time, Hyper/hypo in combination with IMRT (?) - Evidence of relevant shrinkage during RT+CHT (especially in regimens including oxaliplatin), visible with MRI

- Can we exploit T shrinkage to safely boost the residual T ?

Appelt 2012